MAIA Biotechnology, Inc. (MAIA)
Develops cancer drugs that target telomeres to fight lung cancer
$1.24-0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-18.4%
The outlook
MAIA is trading near its 52-week lows and sits below its key moving averages, reflecting weak near-term momentum. Analyst sentiment leans bearish overall, though the average price target suggests significant upside from current levels. The stock remains in early-stage biotech territory with elevated risk.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range16% of the way from its 52-week low to high
Price targetAvg target +879% vs current price
Analyst price target
~12-month · 2 analysts$12.14average target+878.6% vs now
Now $1.24
Low $10.27High $14.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$75.4M
52-wk high
$3.19
52-wk low
$0.87
50-day avg
$1.35
200-day avg
$1.47
Trailing P/E
—